Neuren Pharmaceuticals (NEU) is a great success story and one we can hopefully emulate. Here is a bit of a breakdown of NEU:
NEU develops drugs for a rare condition called Rett Syndrome (RTT) which is a severe neuro-developmental disorder syndrome
It is estimated that 10,000 people in the US suffer from RTT (compared to 250,000 suffering from DMD)
NEU did not start producing income until the 2022 FY and has recorded $200m+ in revenue (FY 23)
NEU went from a low of 10c to a high $25 (currently at $15):
This is an example of how a company's SP can move without producing income. Besides having a successful trial, the main hurdle to replicating these results is the shares on issue. NEU has 127m shares on issue compared to PER which has 901m shares on issue. NEU underwent a consolidation from 1,986,786,305 shares to 99,339,315 shares in 2017 so we should expect something similar to happen to PER at some point in the future.
PER Price at posting:
7.8¢ Sentiment: Hold Disclosure: Held
